Eosinophilic gastroenteritis: Pathogenesis, diagnosis, and treatment

Abstract Eosinophilic gastroenteritis (EGE) is a gastrointestinal disorder of unclear etiology that is characterized by eosinophilic infiltration of the stomach and small intestine, and consists of mucosal, muscular, and serosal subtypes. Eosinophilic infiltration of the gastrointestinal tract is a fundamental histopathological characteristic of EGE and is driven by several T-helper type 2 (Th2)-dependent cytokines and induced by food allergy. Due to the lack of a diagnostic gold standard, EGE has a high rate of delayed diagnosis or misdiagnosis. However, several new diagnostic strategies have been developed, such as novel genetic biomarkers and imaging tests. Although dietary therapy and corticosteroids remain the common choices for EGE treatment, recent decades have seen the emergence of novel treatment alternatives, such as biologics that target particular molecules involved in the pathogenic process. Preliminary investigations and clinical trials have demonstrated the efficacy of biologics and provided additional insights for the era of refractory or corticosteroid-dependent EGE biologics.

[1]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis , 2022, Annals of the Rheumatic Diseases.

[2]  J. Murray,et al.  Eosinophilic Gastroenteritis: Using Presenting Findings to Predict Disease Course , 2021, Clinical and translational gastroenterology.

[3]  Toshio Watanabe,et al.  Gastrointestinal IgG4 Deposition Is a New Histopathological Feature of Eosinophilic Gastroenteritis , 2021, Digestive Diseases and Sciences.

[4]  Emran El-Alali,et al.  Successful use of montelukast in eosinophilic gastroenteritis: a case report and a literature review , 2021, BMC Gastroenterology.

[5]  M. Buras,et al.  Diagnosis of Pediatric Non-Esophageal Eosinophilic Gastrointestinal Disorders by Eosinophil Peroxidase Immunohistochemistry. , 2021, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[6]  E. Dellon,et al.  Peripheral eosinophilia and hypoalbuminemia are associated with a higher biopsy diagnostic yield for eosinophilic gastroenteritis. , 2021, Clinics and research in hepatology and gastroenterology.

[7]  E. Israel,et al.  Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. , 2021, The New England journal of medicine.

[8]  A. Verma,et al.  Tacrolimus (FK506) treatment protects allergen‐, IL‐5‐ and IL‐13‐induced mucosal eosinophilia , 2021, Immunology.

[9]  L. Gehman,et al.  Diagnostic Delay in Patients with Eosinophilic Gastritis and/or Duodenitis: A Population-Based Study. , 2021, The journal of allergy and clinical immunology. In practice.

[10]  Toshio Watanabe,et al.  Endoscopic findings of gastric lesions in patients with eosinophilic gastrointestinal disorders , 2020, Endoscopy International Open.

[11]  J. Murray,et al.  Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. , 2020, The New England journal of medicine.

[12]  E. Dellon,et al.  Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsies From Patients With and Without Eosinophilic Gastroenteritis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  A. Patereli,et al.  Distribution of eosinophils in the gastrointestinal tract of children with no organic disease , 2020, Annals of gastroenterology.

[14]  A. de Silvestri,et al.  Epidemiology of non-esophageal eosinophilic gastrointestinal diseases in symptomatic patients: a systematic review and meta-analysis. , 2020, The journal of allergy and clinical immunology. In practice.

[15]  T. Casale,et al.  Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma , 2020, Allergy.

[16]  Michinobu Umakoshi,et al.  Multiple ulcerations and perforation in the small intestine after steroid treatment in eosinophilic granulomatosis with polyangiitis: a case report and literature review. , 2019, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[17]  C. Băicuș,et al.  Eosinophilic pancreatitis versus pancreatitis associated with eosinophilic gastroenteritis – a systematic review regarding clinical features and diagnosis , 2019, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[18]  J. Krischer,et al.  Association Between Endoscopic and Histologic Findings in a Multicenter Retrospective Cohort of Patients with Non-esophageal Eosinophilic Gastrointestinal Disorders , 2019, Digestive Diseases and Sciences.

[19]  Garrett A. Osswald,et al.  Molecular, Endoscopic, Histologic and Circulating Biomarker-Based Diagnosis of Eosinophilic Gastritis: Multi-Site Study. , 2019, The Journal of allergy and clinical immunology.

[20]  G. Yancopoulos,et al.  Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. , 2019, Gastroenterology.

[21]  C. Bebbington,et al.  Siglec-8 antibody reduces eosinophil and mast cell infiltration in a transgenic mouse model of eosinophilic gastroenteritis. , 2019, JCI insight.

[22]  M. Rezaei-Tavirani,et al.  Evaluation of gene expression change in eosinophilic gastroenteritis , 2019, Gastroenterology and hepatology from bed to bench.

[23]  Prashanth Rawla,et al.  Eosinophilic gastroenteritis: diagnosis and clinical perspectives , 2019, Clinical and experimental gastroenterology.

[24]  A. Straumann,et al.  Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab , 2019, Digestive Diseases and Sciences.

[25]  N. Gonsalves Eosinophilic Gastrointestinal Disorders , 2019, Clinical Reviews in Allergy & Immunology.

[26]  Yu Jin,et al.  Abnormal thymic stromal lymphopoietin expression in the gastrointestinal mucosa of patients with eosinophilic gastroenteritis , 2019, Jornal de pediatria.

[27]  G. Opiteck,et al.  RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. , 2019, Gastroenterology.

[28]  Hiroki Sato,et al.  Clinical and pathological profile of eosinophilic gastroenteritis , 2019, European journal of gastroenterology & hepatology.

[29]  F. Bao,et al.  The Anti-a4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: A Novel Clinical Observation , 2018, American Journal of Gastroenterology.

[30]  G. Furuta,et al.  Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  F. Bao,et al.  The Anti-α4β7 Integrin Therapeutic Antibody for Inflammatory Bowel Disease, Vedolizumab, Ameliorates Eosinophilic Esophagitis: a Novel Clinical Observation , 2018, The American Journal of Gastroenterology.

[32]  M. Furue,et al.  Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis , 2018, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[33]  A. Peters,et al.  Mepolizumab use: Post-approval academic practice experience. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[34]  E. Dellon,et al.  Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  C. Hui,et al.  A Prospective Study on the Prevalence, Extent of Disease and Outcome of Eosinophilic Gastroenteritis in Patients Presenting with Lower Abdominal Symptoms , 2017, Gut and liver.

[36]  A. Vanoli,et al.  Association between defective spleen function and primary eosinophilic gastrointestinal disorders. , 2017, The journal of allergy and clinical immunology. In practice.

[37]  G. Cooper,et al.  Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population‐Based Study, From 2012 to 2017 , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[38]  E. Savarino,et al.  Step‐up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2‐4‐6 study , 2017, The Journal of allergy and clinical immunology.

[39]  N. Ishimura,et al.  Serum Biomarkers for the Diagnosis of Eosinophilic Esophagitis and Eosinophilic Gastroenteritis , 2017, Internal medicine.

[40]  D. King,et al.  Health‐Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  J. Choung,et al.  CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in a Mouse Model of Eosinophilic Gastroenteritis , 2017, Allergy, asthma & immunology research.

[42]  E. Dellon,et al.  Food-specific IgG4 is associated with eosinophilic esophagitis. , 2016, The Journal of allergy and clinical immunology.

[43]  K. Schenck,et al.  Multiple Functions of the New Cytokine-Based Antimicrobial Peptide Thymic Stromal Lymphopoietin (TSLP) , 2016, Pharmaceuticals.

[44]  Y. Ohya,et al.  Sera of patients with infantile eosinophilic gastroenteritis showed a specific increase in both thymic stromal lymphopoietin and IL-33 levels. , 2016, The Journal of allergy and clinical immunology.

[45]  K. Nadeau,et al.  Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange , 2016, Nature Communications.

[46]  Christopher F. Martin,et al.  Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database , 2016, Journal of pediatric gastroenterology and nutrition.

[47]  K. Lim,et al.  Eosinophilic gastroenteritis: Clinical profiles and treatment outcomes, a retrospective study of 18 adult patients in a Singapore Tertiary Hospital. , 2015, The Medical journal of Malaysia.

[48]  Reiji Kojima,et al.  Racial differences in eosinophilic gastrointestinal disorders among Caucasian and Asian. , 2015, Allergology international : official journal of the Japanese Society of Allergology.

[49]  R. Yu,et al.  Eosinophilic gastroenteritis associated with eosinophilic cystitis: Computed tomography and magnetic resonance imaging findings. , 2015, World journal of gastroenterology.

[50]  K. Nadeau,et al.  Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. , 2015, The Journal of allergy and clinical immunology.

[51]  J. Arm,et al.  Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[52]  F. Clayton,et al.  Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. , 2014, Gastroenterology.

[53]  C. Lai,et al.  Eosinophilic gastroenteritis with involvement of the urinary bladder , 2014, Pediatric Radiology.

[54]  N. Ishimura,et al.  Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan , 2013, Journal of clinical biochemistry and nutrition.

[55]  A. Straumann,et al.  Anti‐eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis , 2013, Allergy.

[56]  M. Vogel,et al.  Accelerated Disassembly of IgE:Receptor Complexes by a Disruptive Macromolecular Inhibitor , 2012, Nature.

[57]  James B. Young,et al.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. , 2012, The Journal of allergy and clinical immunology.

[58]  P. Desreumaux,et al.  Natural history of eosinophilic gastroenteritis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[59]  H. Ortega,et al.  An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. , 2011, Gastroenterology.

[60]  B. Medoff,et al.  18F-FDG Uptake Rate Is a Biomarker of Eosinophilic Inflammation and Airway Response in Asthma , 2011, The Journal of Nuclear Medicine.

[61]  D. Morgan,et al.  Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. , 2011, Gastroenterology.

[62]  Yuzhi Yin,et al.  Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders , 2011, Clinical and molecular allergy : CMA.

[63]  Samir S. Shah,et al.  Variation in Prevalence, Diagnostic Criteria, and Initial Management Options for Eosinophilic Gastrointestinal Diseases in the United States , 2011, Journal of pediatric gastroenterology and nutrition.

[64]  C. Prussin,et al.  Eosinophilic gastrointestinal disease and peanut allergy are alternatively associated with IL-5+ and IL-5(-) T(H)2 responses. , 2009, The Journal of allergy and clinical immunology.

[65]  C. Beglinger,et al.  Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial , 2009, Gut.

[66]  G. Kearns,et al.  Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: Effect on eosinophil density and activation in relation to pharmacokinetics , 2009, BMC gastroenterology.

[67]  B. Ruebner,et al.  Unusual presentations of eosinophilic gastroenteritis: case series and review of literature. , 2009, World journal of gastroenterology.

[68]  K. Stone,et al.  Immunomodulatory therapy of eosinophil‐associated gastrointestinal diseases , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[69]  R. Weimann,et al.  Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission , 2007, European journal of gastroenterology & hepatology.

[70]  Nayoung Kim,et al.  Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. , 2007, The Journal of allergy and clinical immunology.

[71]  T. Sentongo,et al.  Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[72]  H. Simon,et al.  Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. , 2006, The Journal of allergy and clinical immunology.

[73]  M. Rothenberg,et al.  The α4bβ7‐integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[74]  J. Bousquet,et al.  The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. , 2005, The Journal of allergy and clinical immunology.

[75]  S. Hogan,et al.  Review article: the eosinophil as a therapeutic target in gastrointestinal disease , 2004, Alimentary pharmacology & therapeutics.

[76]  B. Bochner,et al.  Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. , 2003, Blood.

[77]  A. Zinsmeister,et al.  Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues. , 1990, Gut.

[78]  M. Sleisenger,et al.  EOSINOPHILIC GASTROENTERITIS , 1970, Medicine.

[79]  L. Spencer,et al.  Assessing Phenotypic Heterogeneity in Intestinal Tissue Eosinophils. , 2021, Methods in molecular biology.

[80]  H. Sampson,et al.  Adverse reactions to foods. , 2006, The Medical clinics of North America.